Contrasting PolyPid (NASDAQ:PYPD) & Dyne Therapeutics (NASDAQ:DYN)

PolyPid (NASDAQ:PYPD) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Analyst Ratings

This is a summary of recent recommendations and price targets for PolyPid and Dyne Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1	0	6	1	2.88
Dyne Therapeutics	1	3	10	4	2.94

PolyPid presently has a consensus target price of $12.40, suggesting a potential upside of 214.72%. Dyne Therapeutics has a consensus target price of $35.47, suggesting a potential upside of 71.75%. Given PolyPid’s higher probable upside, equities analysts clearly believe PolyPid is more favorable than Dyne Therapeutics.

Institutional and Insider Ownership

26.5% of PolyPid shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares PolyPid and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-313.65%	-128.32%
Dyne Therapeutics	N/A	-66.17%	-56.35%

Risk and Volatility

PolyPid has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Valuation & Earnings

This table compares PolyPid and Dyne Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$29.02 million	($2.98)	-1.32
Dyne Therapeutics	N/A	N/A	-$317.42 million	($3.66)	-5.64

Dyne Therapeutics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.